Corticosteroids for IBD

Video

Are corticosteroids still the number one drug for inducing clinical remission in IBD?

Are corticosteroids still the number one drug for inducing clinical remission in IBD? Find out in this video.

Recent Videos
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Image credit: Gorodenkoff | stock.adobe.com
Pharmacist and Patient in Pharmacy | Image Credit: Gorodenkoff - stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Related Content
FDA Approval | Image Credit: outchill - stock.adobe.com

FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease

Ashley Gallagher, Associate Editor
July 24th 2024
Article
Pharmacy Focus: What to Know About Medication and Summer Travel

Pharmacy Focus: What to Know About Medication and Summer Travel

July 12th 2024
Podcast
Coagulation Factor VIII, FVIII, an essential blood-clotting protein, also known as anti-hemophilic factor, AHF, 3D illustration

Intravenous Immunoglobulin Temporarily Improves Bleeding in Patients With Acquired Von Willebrand Syndrome

Luke Halpern, Assistant Editor
July 24th 2024
Article
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

June 27th 2024
Podcast
Study Shows Value of Investing in Pharmacogenomics Testing for Tacrolimus Dosing in Kidney Transplant Recipients

Study Shows Value of Investing in Pharmacogenomics Testing for Tacrolimus Dosing in Kidney Transplant Recipients

Alexander McCarthy, PharmD
July 19th 2024
Article
Drug-related adverse events, community pharmacy | Image Credit: sutlafk - stock.adobe.com

Better Prevention Strategies Rely on the Monitoring of Outpatient Adverse Drug Events

Ashley Gallagher, Associate Editor
July 17th 2024
Article